Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua F Zeidner

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|October 16, 2019
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approachDaniel J Lee, Joshua F Zeidner
Leukemia & Lymphoma|March 26, 2015
Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantJoshua F Zeidner, B Douglas Smith
Cardiology in Review|August 19, 2008
Investigational antiplatelet drugs for the treatment and prevention of coronary artery diseaseJoshua F Zeidner, William H Frishman, Robert G Lerner
Current Cancer Drug Targets|April 23, 2020
Immune Checkpoint Inhibitors in AML-A New FrontierRohit Thummalapalli, Hanna A Knaus, Ivana Gojo, et al.
Leukemia & Lymphoma|May 24, 2019
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET)Ranjit Joseph, Autumn J McRee, Stephanie Mathews, et al.
Current Treatment Options in Oncology|March 17, 2026
Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid LeukemiaDaniel T Peters, Jess Hatfield, Mollie Reese, et al.
Current Hematologic Malignancy Reports|February 20, 2021
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment OptionsDaniel R Richardson, Steven D Green, Matthew C Foster, et al.
Seminars in Oncology Nursing|November 25, 2019
Advances in Genomic Profiling and Risk Stratification in Acute Myeloid LeukemiaDaniel R Richardson, Matthew C Foster, Catherine C Coombs, et al.
Expert Review of Hematology|May 27, 2021
CD123-targeted therapy in acute myeloid leukemiaManuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F Zeidner, et al.
The American Journal of Medicine|April 20, 2010
The tissue's the issueJoshua F Zeidner, Edwin J Ostrin, Emily Sydnor, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|October 16, 2019
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approachDaniel J Lee, Joshua F Zeidner
Leukemia & Lymphoma|March 26, 2015
Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantJoshua F Zeidner, B Douglas Smith
Cardiology in Review|August 19, 2008
Investigational antiplatelet drugs for the treatment and prevention of coronary artery diseaseJoshua F Zeidner, William H Frishman, Robert G Lerner
Current Cancer Drug Targets|April 23, 2020
Immune Checkpoint Inhibitors in AML-A New FrontierRohit Thummalapalli, Hanna A Knaus, Ivana Gojo, et al.
Leukemia & Lymphoma|May 24, 2019
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET)Ranjit Joseph, Autumn J McRee, Stephanie Mathews, et al.
Current Treatment Options in Oncology|March 17, 2026
Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid LeukemiaDaniel T Peters, Jess Hatfield, Mollie Reese, et al.
Current Hematologic Malignancy Reports|February 20, 2021
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment OptionsDaniel R Richardson, Steven D Green, Matthew C Foster, et al.
Seminars in Oncology Nursing|November 25, 2019
Advances in Genomic Profiling and Risk Stratification in Acute Myeloid LeukemiaDaniel R Richardson, Matthew C Foster, Catherine C Coombs, et al.
Expert Review of Hematology|May 27, 2021
CD123-targeted therapy in acute myeloid leukemiaManuel Ricardo Espinoza-Gutarra, Steven D Green, Joshua F Zeidner, et al.
The American Journal of Medicine|April 20, 2010
The tissue's the issueJoshua F Zeidner, Edwin J Ostrin, Emily Sydnor, et al.
Pageof 8